KURA Earnings & Financial Statements
Kura Oncology, Inc.
$10.67
+$0.14(+1.33%)
32
Overall
60
Value
20
Tech
18
Quality
Market Cap
$936.76M
Volume
1.10M
52W Range
$7.36 - $13.90
Target Price
$31.85
KURA earnings and financial statements: Kura Oncology, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
KURA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $67.48M | $53.88M | - | - | - |
| Cost of revenue | $57.0K | - | - | - | - |
| Operating income | -$303.63M | -$193.19M | -$165.80M | -$139.87M | -$131.26M |
| EBITDA | -$275.34M | -$169.02M | -$160.83M | -$144.46M | -$129.49M |
| Net income | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -$130.47M |
| EPS (diluted) | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $738.36M | $760.16M | $448.94M | $456.31M | $534.05M |
| Total liabilities | $564.23M | $346.52M | $51.66M | $36.03M | $27.44M |
| Shareholders’ equity | $174.13M | $413.64M | $397.27M | $420.28M | $506.61M |
| Cash and equivalents | $149.10M | $224.46M | $37.32M | $51.80M | $90.67M |
| Long-term debt | $19.18M | $12.11M | $15.69M | $11.71M | $4.61M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$64.06M | $134.32M | -$124.82M | -$110.06M | -$104.55M |
| Capital expenditure | -$6.64M | -$472.0K | -$168.0K | -$626.0K | -$1.15M |
| Free cash flow | -$70.70M | $133.84M | -$124.99M | -$110.69M | -$105.70M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KURA | $10.67 | +1.3% | 1.10M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |